Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Aduhelm (Aducanumab) is a medication developed for the treatment of Alzheimer's disease, which is characterized by memory loss and cognitive decline. As a type of monoclonal antibody, Aduhelm targets amyloid beta plaques—protein deposits typically found in the brains of people with Alzheimer's—and helps reduce their buildup. Aduhelm may help slow the progression of Alzheimer’s. It falls under the class of monoclonal antibodies.
Aduhelm is administered via intravenous infusion over approximately one hour. Health professionals typically start with an initial dosage of 1 milligram (mg) per kilogram (kg) of the patient's body weight once every four weeks. The dosage gradually increases to 3 mg/kg, then 6 mg/kg, and finally to a maintenance dose of 10 mg/kg based on tolerability.
It’s recommended to undergo monitoring for amyloid-related imaging abnormalities (ARIA) during treatment, which includes MRI scans before the 5th, 7th, 9th, and 12th infusions. Because of potential side effects, caregivers should be attentive to any changes in health and report them to the healthcare provider.
The main ingredient in Aduhelm is aducanumab-avwa. Inactive ingredients may include L-arginine hydrochloride, L-histidine, polysorbate 80, and water for injection, among others.
There are no known contraindications for Aduhelm.
The use of Aduhelm may cause side effects. Common Aduhelm side effects are associated with amyloid-related imaging abnormalities. These side effects may include headaches, confusion, nausea, dizziness, vision changes, and seizures. Monitor these side effects closely as they may indicate the body’s reaction to Aduhelm. Seek medical attention if side effects develop, persist, or worsen.